Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

NCT03331289 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the drug exenatide can prevent an increase in blood sugar production in adults with type 2 diabetes when another drug, dapagliflozin, causes more sugar to be lost in the urine.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 107 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2018-02 · est. completion 2022-11

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03331289 ↗

Description as written by the study sponsor.

Research Design/Plan: After screening, each subject will receive 1 measurements of Endogenous Glucose Production \[EGP\] with prime-continuous Infusion of 3-3H-glucose. After completing the EGP measurement each subject will receive a Double Tracer Oral Glucose Tolerance Test \[OGTT\]. Methods: Visit 1: Screening. Medical history will be obtained, physical exam performed, and pregnancy test performed. Visit 2: Endogenous Glucose Production Measurement: The rate of EGP will be measured with 3-3H-glucose. Visit 3: Double Tracer OGTT

Treatments tested

Placebo also known as Placebo drug Drug

Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period
Exenatide also known as Byetta, Bydureon Drug

Exenatide will be administered to 20 subjects after a 3 hour tracer equilibration period
Dapagliflozin also known as Farxiga Drug

Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
Exenatide and Dapagliflozin also known as Byetta plus Dapagliflozin Drug

Exenatide and Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period

Main thing measured	Change in EGP From Baseline to Post-oral Glucose Load.
Sponsor	The University of Texas Health Science Center at San Antonio
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03331289 ↗